A Phase 1 interventional study of Duvelisib in Mycosis Fungoides and Cutaneous T-cell Lymphoma, sponsored by SecuraBio. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-20.
Sponsored by SecuraBio · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 360 studies in Mycosis Fungoides with a site in United States — 24 open to participants now, 36 under way, none of them phase 3. Mycosis Fungoides · United States.
Among the 360 studies in Mycosis Fungoides with a site in United States, this one is the 141st largest by planned enrollment of the 279 interventional ones that give a count, is one of 2 that started in 2027, is one of 131 in phase 1, reaches primary completion later than 25 of the 35 other live ones, and was the 359th registered.
447 studies on the registry are indexed under Mycosis Fungoides; 42 are open to participants now.
Browse Mycosis Fungoides studies →24 of the 360 studies in Mycosis Fungoides with a site in United States are open now. Recruiting first, the newest first:
Kyowa Kirin, Inc. · Sites in United States, Italy, Spain
Ages 18+
Prescient Therapeutics, Ltd. · Sites in United States, Australia, France and 1 more country
Ages 18+
City of Hope Medical Center · Sites in United States
Ages 18+
University of California, Irvine · Sites in United States
Ages 18+
M.D. Anderson Cancer Center · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 30 Mycosis Fungoides studies recruiting now, 25 (83%) set no upper age limit and 1 (3%) stops at 75 or younger; 2 take children under 18; 3 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
360 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 164 · Phase 2 135 · Phase 3 20 · Phase 4 4
First in 1988; this study’s year is marked. 2 started in 2027.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is below the median of 34 across 321 interventional studies indexed under Mycosis Fungoides.
Median enrollment 32 across the 279 interventional studies, 65 across the 34 observational. Of the 301 that completed or were terminated, 95 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
50 of 360 have an industry lead sponsor. The 10 most frequent:
SecuraBio is the lead sponsor of 25 studies on the registry; 2 are open to participants now.
SecuraBio has 1 study filed under Mycosis Fungoides — fewer than ten, so there is no comparison to draw.
12 of the studies in Mycosis Fungoides with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04256018Stanford UniversityMogamulizumab + Low-Dose Total Skin Electron Beam Tx in Mycosis Fungoides & Sézary Syndrome | 2026-12 |
| NCT07003100City of Hope Medical CenterA Prospective, US-based Study Assessing Mogamulizumab-associated Rash in Patients Diagnosed With Mycosis Fungoides or Sezary Syndrome and Treated With Standard of Care Mogamulizumab | 2027-01-12 |
| NCT05357794M.D. Anderson Cancer CenterEffectiveness of Concurrent Ultra-Low-Dose Total-Skin Electron Beam Therapy and Brentuximab Vedotin Given Quarterly Over 12 Months for Patients With Mycosis Fungoides | 2027-01-30 |
| NCT05944562Washington University School of MedicineTulmimetostat (DZR123) in Patients With Mycosis Fungoides and Sézary Syndrome | 2027-02-28 |
| NCT05680558Columbia UniversityPhotopheresis in Early-stage Mycosis Fungoides | 2027-03 |
Add all 12 to your calendar (.ics) → With an account.
Among the 360 studies in Mycosis Fungoides with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will evaluate the safety and preliminary efficacy of duvelisib topical gel in participants with early-stage mycosis fungoides.
Key Inclusion Criteria:
Key Exclusion Criteria:
Note: other protocol-defined criteria apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Duvelisib
Topical gel
Also known as: SBI-0145
Number of Participants with Treatment-emergent Adverse Events (TEAEs)
Time frame: Baseline through Day 114
Local Skin Reactions to Duvelisib Topical Gel
Local skin reactions will be measured as a local skin reaction score using a four-point post-treatment assessment severity scale.
Time frame: After each treatment administration up to Day 114
Maximum Tolerated Dose (MTD) of Duvelisib Topical Gel
Time frame: Up to 28 days
Recommended Phase 2 Dose (RP2D) of Duvelisib Topical Gel
Time frame: Up to 28 days
Pharmacokinetics: Plasma Concentration of Duvelisib Topical Gel
Time frame: Days 1, 2, and 28 (pre-dose, up to 6 hours post-dose)
Pharmacokinetics: Maximum Plasma Concentration (Cmax) of Duvelisib Topical Gel
Time frame: Days 1, 2, and 28 (pre-dose, up to 6 hours post-dose)
Pharmacokinetics: Time to Maximum Plasma Concentration (Tmax) of Duvelisib Topical Gel
Time frame: Days 1, 2, and 28 (pre-dose, up to 6 hours post-dose)
Pharmacokinetics: Area Under the Curve (AUC) of Duvelisib Topical Gel
Time frame: Days 1, 2, and 28 (pre-dose, up to 6 hours post-dose)
Proportion of Treated Lesions Achieving >50% Improvement from Baseline Based on Modified Composite Assessment of Index Lesion Severity (mCAILS) Score
Time frame: Baseline through Day 114
Number of Participants Achieving a ≥50% Reduction from Baseline in Total mCAILS Score
Time frame: Baseline through Day 114
Change from Baseline in Total Modified Severity-weighted Assessment Tool (mSWAT) Score
Time frame: Baseline, Day 114
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Jan 2027; primary completion for Oct 2028, 21 months later.
Of 29 phase 1 interventional studies under Mycosis Fungoides, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 80. This study's planned 21 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Duvelisib